Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Change in fair value of contingent consideration by Quarter
Change in fair value of contingent consideration liabilities ($M) ($M)
Vertex Pharmaceuticals Change in fair value of contingent consideration: $0.40M in Q2 2026, down 55.6% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Fair Value Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Change in fair value of contingent consideration liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0.40 | -55.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 0.20 | -90.9% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 0.90 | -175.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.90 | -733.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 0.90 | +80.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 2.20 | -2,300.0% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | -1.20 | -97.6% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 0.30 | -75.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 0.50 | -183.3% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | -0.10 | -94.7% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | -50.3 | -2,894.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 1.20 | -146.2% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | -0.60 | -98.8% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | -1.90 | -74.7% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 1.80 | -190.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | -2.60 | -316.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | -49.2 | -3,175.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | -7.50 | +92.3% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | -2 | -500.0% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 1.20 | -33.3% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 1.60 | -82.6% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | -3.90 | -343.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 0.50 | -66.7% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2020 | Sep 30, 2020 | 1.80 | -40.0% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 9.20 | – | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 1.60 | – | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 1.50 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2019 | Sep 30, 2019 | 3 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q2 2019 | Jun 30, 2019 | 0 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q1 2019 | Mar 31, 2019 | 0 | -100.0% | Form 10-K (filed 2021-02-11) ↗ |
| Q4 2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2018 | Sep 30, 2018 | 0 | – | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 0 | – | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 24 | – | Form 10-Q (filed 2019-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Change in fair value of contingent consideration ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-fv-change
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.